A Phase 2, Exploratory Study Evaluating the Safety and Antiviral Efficacy of Inarigivir Soproxil in Non-cirrhotic Treatment-Naive Subjects Infected With Chronic Hepatitis B Virus
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Inarigivir soproxil (Primary) ; Tenofovir alafenamide (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- Acronyms CATALYST 1
- Sponsors F-star Therapeutics; Spring Bank Pharmaceuticals
Most Recent Events
- 29 Jan 2020 According to a Spring Bank Pharmaceuticals media release, the company has discontinued development of inarigivir soproxil, which was in Phase 2 development for the treatment of chronic hepatitis B virus (HBV). This decision was made in the interest of patient safety based on the occurrence of unexpected serious adverse events, including one patient death, in Spring Banks Phase 2b CATALYST trial.
- 26 Dec 2019 Status changed from recruiting to discontinued as per Spring Bank Pharmaceuticals.
- 15 Oct 2019 Status changed from not yet recruiting to recruiting.